Envafolimab

Envafolimab
Monoclonal antibody
Type	Single-chain variable fragment
Target	PD-L1
Clinical data
Drug class	Antineoplastic agent
ATC code	L01FF15 ( WHO );
Identifiers
CAS Number	2102192-68-5 ;
PubChem CID	381609252 ;
DrugBank	DB15769 ;
UNII	ES1M06M6QH ;

Last updated December 24, 2025

Envafolimab is an anti-PD-L1 nanobody used in cancer immunotherapy.^[1] It has been approved in China for the treatment of microsatellite instability-high (MSI-H) or MisMatch Repair deficient (dMMR) solid tumours.^[2] Envafolimab (KN035) has obtained the US FDA's orphan drug designation for advanced biliary tract cancer.

References

↑ "Envafolimab - Alphamab Oncology/Ascletis/3D Medicine". AdisInsight. Springer Nature Switzerland AG.
↑ Markham A (February 2022). "Envafolimab: First Approval". Drugs. 82 (2): 235–240. doi:10.1007/s40265-022-01671-w. PMID 35122636. S2CID 246534311.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Envafolimab - Alphamab Oncology/Ascletis/3D Medicine". AdisInsight. Springer Nature Switzerland AG.

[pmid35122636-2] Markham A (February 2022). "Envafolimab: First Approval". Drugs. 82 (2): 235–240. doi:10.1007/s40265-022-01671-w. PMID 35122636. S2CID 246534311.

[1]

[2]